Abstract Number: 8L • ACR/ARHP Annual Meeting 2016
A Randomized, Double-Blind, Placebo-Controlled Study of Bimagrumab in Patients with Sporadic Inclusion Body Myositis
Anthony A. Amato1, Umesh Badrising2, Olivier Benveniste3, Merrilee Needham4, Hector Chinoy5, Min Wu6, Barbara Koumaras6, Ana de Vera7, Dimitris A. Papanicolaou6 and Michael G. Hanna8, 1Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 2Department of Neurology, Leiden University Medical Center, Leiden, Netherlands, 3Department of Internal Medicine, Pitié-Salpêtrière Hospital, Pierre et Marie-Curie University, Paris, France, 4Fiona Stanley Hospital, IIID Murdoch University and Notre Dame University, Perth, Australia, 5Centre for Musculoskeletal Research, NIHR Manchester Musculoskeletal Biomedical Research Unit, The University of Manchester, Manchester, United Kingdom, 6Novartis Pharmaceuticals Corporation, East Hanover, NJ, 7Novartis Pharma AG, Basel, Switzerland, 8MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology, London, United Kingdom
Background/Purpose: Bimagrumab (BYM338) is a novel fully human monoclonal antibody that binds competitively to activin type II receptors with greater affinity than natural inhibitory ligands…
ACR Meeting Abstracts